- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Alps Group Inc(ALPS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ALPS
11/13/2026: ALPS (1-star) is currently NOT-A-BUY. Pass it for now.
Alps Group Inc is a micro-cap biotechnology and healthcare company headquartered in Malaysia that integrates advanced molecular research, genomics, and clinical wellness services. The company's primary business strengths lie in its accredited MyGenome whole genome sequencing capabilities and expanding suite of precision medicine solutions. Its core growth story centers on capitalizing on rising regional demand for preventive healthcare and precision oncology. However, the company faces notable risks, including persistent net losses, micro-cap share volatility, and intense competition from established global diagnostics firms. The stock may best suit speculative or momentum-oriented investors willing to monitor clinical execution and cash burn developments closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers exposure to expanding biotech and genomics markets, but its micro-cap scale introduces execution uncertainties. |
| Momentum investor | Strong fit while signal remains positive | Low-float micro-cap biotech shares can experience sharp momentum-driven price movements when positive clinical news occurs. |
| Value investor | Weak fit | The lack of consistent net profitability and negative earnings make it unsuitable for traditional value investing metrics. |
| Dividend investor | Weak fit | The company pays no dividends and retains all capital to fund research and business operations. |
| Low-risk investor | Weak fit | High share price volatility and micro-cap status expose investors to significant downside risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock exhibits high historical price swings and sensitivity typical of micro-cap equities. |
| Valuation risk | Medium / high | Negative earnings and early-stage revenues complicate traditional fundamental valuation. |
| Competition risk (diagnostics and genomics competition) | High | The company competes with well-funded global diagnostics and biotechnology giants. |
| Business quality | Medium | Integrated operations and certified labs provide a sound foundation, but overall scale is modest. |
| Dividend income | Low / none | No dividend distributions are offered to shareholders. |
| Execution risk | High | Success depends heavily on commercializing new genomic tests and scaling clinical facilities profitably. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.38M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 18.4K shares | Beta - | 52 Weeks Range 1.01 - 8.60 | Updated Date 11/15/2026 |
52 Weeks Range 1.01 - 8.60 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Sector & Industry Intelligence
Sector intelligence is unavailable for this snapshot.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 0 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Medical and Wellness Services | Non-surgical and surgical aesthetic treatments, medical consultations, health screenings, and cellular therapy. | This segment provides the core near-term clinical and wellness service revenues. |
| Life Science and Genomics | Whole-genome sequencing, pharmacogenomics, and patient-derived organoid testing. | This segment drives the higher-margin scientific research and advanced diagnostics potential. |
| Geographic Exposure (Malaysia) | Clinical laboratories, medical centers, and wellness hubs primarily anchored in Malaysia. | Operations are currently regional, concentrating execution exposure in Southeast Asia. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37.33M | Price to Sales(TTM) 8.09 |
Enterprise Value 37.33M | Price to Sales(TTM) 8.09 | ||
Enterprise Value to Revenue 7.69 | Enterprise Value to EBITDA - | Shares Outstanding 3.00M | Shares Floating - |
Shares Outstanding 3.00M | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

